Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars ↗

February 28, 2025

Amneal Pharmaceuticals' Q4 sales rose 18% to $730.52M, surpassing estimates, while adjusted EPS missed. The company forecasts up to $3.1B in 2025 revenue.

Via Benzinga

Amneal’s (NASDAQ:AMRX) Q4 Sales Beat Estimates, Guides for Strong Full-Year Sales

February 28, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 18.4% year on year to $730.5 million. The company’s...

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

February 28, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what investors should know.

Earnings Outlook For Amneal Pharmaceuticals ↗

November 07, 2024

Via Benzinga

What's Next: Amneal Pharmaceuticals's Earnings Preview ↗

November 07, 2024

Via Benzinga

Earnings Scheduled For February 28, 2025 ↗

February 28, 2025

Via Benzinga

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 27, 2025

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock ↗

February 24, 2025

JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million.

Via Benzinga

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

February 21, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...

Topics Artificial Intelligence Intellectual Property

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

February 19, 2025

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

February 19, 2025

Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

Topics Artificial Intelligence Intellectual Property

February 14, 2025

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.

ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group

Topics Artificial Intelligence Intellectual Property

February 13, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.

Topics Artificial Intelligence Intellectual Property

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

January 29, 2025

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

January 23, 2025

CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗

January 06, 2025

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions.

Via Benzinga

Topics Lawsuit

Amneal to Participate at Upcoming Investor Conferences

December 04, 2024

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

November 21, 2024

Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus, driven by strong launches and specialty growth.

Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts ↗

November 08, 2024

Via Benzinga

Amneal Reports Third Quarter 2024 Financial Results

November 08, 2024

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

October 21, 2024

Amneal to Report Third Quarter 2024 Results on November 8, 2024

October 08, 2024

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

October 01, 2024

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

September 24, 2024

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END

Via FinancialNewsMedia

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

September 24, 2024

From FN Media Group LLC

Via GlobeNewswire

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease

September 23, 2024

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗

September 06, 2024

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.

Via Benzinga

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

September 05, 2024

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

August 20, 2024